News and Events

Guest User 9/21/22 Guest User 9/21/22

C₂N Diagnostics Partners with Grupo Fleury to Bring Pioneering Blood Tests to Brazil for Advancing Brain Health

Guest User 9/14/22 Guest User 9/14/22

Independent Research Finds Underlying Method for C₂N’s p-Tau217 RatioBlood Test Outperforms Other Tau Blood Tests Used for Alzheimer’s Diagnoses

Guest User 8/30/22 Guest User 8/30/22

C₂N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia

Guest User 8/23/22 Guest User 8/23/22

C₂N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings

Guest User 7/31/22 Guest User 7/31/22

C₂N Data Release for New Blood Test Combining p-tau217 Ratio with Amyloid beta 42/40

Guest User 5/18/22 Guest User 5/18/22

C₂N Diagnostics Introduces P-tau Multi-Analyte Assay for Research Use Only to Advance Alzheimer’s Disease and Brain Health Field

Tim West 4/21/22 Tim West 4/21/22

JAMA Network Open Publishes Analysis of Results of Two Independent Studies Demonstrating the High Diagnostic Performance of the PrecivityAD™ Blood Test for Alzheimer’s Disease

Guest User 2/22/22 Guest User 2/22/22

C₂N Achieves ISO 13485:2016 Certification Latest Development for Leader in Brain Health Sector

Guest User 1/3/22 Guest User 1/3/22

C₂N Begins New Year with CAP Accreditation Award, the Highest Standard in Laboratory Practices

Tim West 11/12/21 Tim West 11/12/21

Major Research Findings Highlight Effectiveness of the PrecivityAD™ Blood Test That Clinicians Use to Aid in Alzheimer’s Disease Diagnosis

Tim West 9/21/21 Tim West 9/21/21

C₂N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology

Joni Henderson 7/29/21 Joni Henderson 7/29/21

Two Research Studies Bolster Method That C2N’s PrecivityAD™ Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses

Joni Henderson 7/21/21 Joni Henderson 7/21/21

Blood tests could help screen anticipated flood of patients seeking new Alzheimer’s drug

Joni Henderson 5/27/21 Joni Henderson 5/27/21

Peer-Reviewed Journal Publishes Analytical Validation Results for thePrecivityAD™ Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease

Joni Henderson 5/5/21 Joni Henderson 5/5/21

Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis

Tim West 4/29/21 Tim West 4/29/21

Rhode Island Patients Now Have Access to Breakthrough Alzheimer’s Diagnostic Blood Test

Adam Shapiro 3/8/21 Adam Shapiro 3/8/21

C2N Diagnostics, Boosted by Growth from the PrecivityAD™ Blood Test, Named By Fierce Medtech As a ‘Fierce 15’

Joni Henderson 12/8/20 Joni Henderson 12/8/20

PrecivityAD™ Blood Test’s Reach Expands to Europe and California Following Initial Launch; Test Detects Alzheimer’s Disease Pathology

Joni Henderson 10/29/20 Joni Henderson 10/29/20

Alzheimer’s Breakthrough: C₂N First to Offer a Widely Accessible Blood Test

A breakthrough in Alzheimer’s disease has arrived with C2N Diagnostics’ PrecivityAD™ blood test into the clinic. The PrecivityAD™ test is a highly sensitive Alzheimer’s blood test using mass spectrometry and is performed in a CLIA-certified lab. The PrecivityAD™ test is easy to administer, does not involve any radiation, and is non-invasive. These features are expected to make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.

Joni Henderson 9/26/20 Joni Henderson 9/26/20

ADDF Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer’s

C₂N Diagnostics has been awarded more than $2.2 million to accelerate clinical validation and accreditation of its beta-amyloid blood test.